Nanostructured lipid carriers (NLC) of Glimepiride was prepared with the objective of treating type-2 diabetes. The formulated NLC consist of Compritol ATO 888 as solid lipid, medium chain triglycerides as liquid lipid and poloxamer 188 as surfactant. NLC’s were prepared by using hot homogenization technique and characterized by FT-IR, DSC. All NLC had shown entrapment efficiency within a range of 78.52 to 90.38%. Both entrapment efficiency and release rate was effected by lipid concentration. Formulation F5 was considered as an optimized formulation based on its particle size and % drug release. Zeta potential value had suggested good particle stability. The optimized formulation did not show any physical/chemical changes when it is subjected to accelerated stability conditions. It was concluded that formulated NLC holds as a potential approach for controlled release of drug which may reduce the dose frequency and improves patient compliance.
